id: NEW:myo_inositol_treatment_to_NEW:pcos_metabolic_profile
name: Myo-Inositol Treatment â†’ PCOS Metabolic Profile
from_node:
  node_id: NEW:myo_inositol_treatment
  node_name: Myo-Inositol Treatment
to_node:
  node_id: NEW:pcos_metabolic_profile
  node_name: PCOS Metabolic Profile
direction: negative
category: biological
mechanism_pathway:
- 'Step 1: Myo-inositol administered as food supplement for PCOS'
- 'Step 2: Acts as insulin sensitizer to improve insulin signaling'
- 'Step 3: Equivalent effects on fasting insulin, HOMA index, and testosterone as metformin'
- 'Step 4: Improved androgenic and metabolic profile with better tolerability'
evidence:
  quality_rating: A
  n_studies: 6
  primary_citation: 'Fabio Facchinetti et al. 2019. "Short-term effects of metformin and myo-inositol
    in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials.."
    https://doi.org/10.1080/09513590.2018.1540578'
  supporting_citations:
  - Additional citations require full-text access - meta-analysis included 6 RCTs comparing MET to MI
  - Studies conducted from 1994-2017 identified via MEDLINE, Cochrane Library, PubMed
  - Individual study citations available in full-text systematic review
  doi: 10.1080/09513590.2018.1540578
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: 'Meta-analysis found no significant difference between metformin and myo-inositol on fasting
  insulin (SMD=0.08, 95% CI: -0.31-0.46, p=.697), indicating equivalent short-term metabolic effects.
  Myo-inositol, as a food supplement, provides comparable efficacy with better tolerability.'
quantitative_effects:
  effect_size:
    value: 0.08
    type: standardized_mean_difference
    ci_lower: -0.31
    ci_upper: 0.46
  p_value: 0.697
  sample_size: 355
structural_competency:
  equity_implications: Access to myo-inositol as a food supplement rather than prescription medication
    may reduce barriers related to healthcare access, prescription costs, and medical system navigation.
    This has equity implications for women in underserved areas or without adequate insurance coverage.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.985174'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
